Eyenovia (NASDAQ:EYEN) Posts Quarterly Earnings Results, Beats Estimates By $5.61 EPS

Eyenovia (NASDAQ:EYEN) issued its quarterly earnings results on Monday. The company reported ($1.59) EPS for the quarter, topping the consensus estimate of ($7.20) by $5.61, Zacks reports. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%.

Eyenovia Stock Performance

Shares of EYEN remained flat at $1.13 during mid-day trading on Monday. 2,021,096 shares of the company traded hands, compared to its average volume of 170,692. Eyenovia has a 52-week low of $0.85 and a 52-week high of $124.80. The stock has a market cap of $3.20 million, a PE ratio of -0.02 and a beta of 0.76. The firm’s fifty day simple moving average is $1.18 and its 200 day simple moving average is $6.23. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.58.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating and set a $2.00 price target on shares of Eyenovia in a research report on Friday, March 21st.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.